McKessonRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
McKesson (MCK) reported revenue of $96.30B in Q1 2026, with North American Pharmaceutical its largest revenue segment at 85%.
McKessonLargest US pharmaceutical distributor by revenue, with oncology and specialty provider platforms alongside core wholesale. Management attributes much of recent revenue growth to GLP-1 adoption plus branded pharmaceutical demand, though the products carry thin distribution margins.
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Q2 2024-Q1 2026
McKesson (MCK) is a Medical - Distribution company. Largest US pharmaceutical distributor by revenue, with oncology and specialty provider platforms alongside core wholesale. Management attributes much of recent revenue growth to GLP-1 adoption plus branded pharmaceutical demand, though the products carry thin distribution margins. It was founded in 1833, is headquartered in Irving, TX and employs about 43,000 people.
As of 2026-Q1, McKesson's revenue breaks down across North American Pharmaceutical (85%), Oncology & Multispecialty (12%), Prescription Technology Solutions (2%), Medical-Surgical Solutions (2%). See the revenue-by-segment chart for the full mix.
Track McKesson's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups McKesson in the GLP-1 sector, alongside Hims & Hers Health (HIMS), Cencora (COR), Cardinal Health (CAH) and CVS Health (CVS).
If you are researching McKesson, also look at Hims & Hers Health (HIMS), Cencora (COR) and Cardinal Health (CAH). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.